List view / Grid view
In this Q&A, Laure Pomares Voisin, Quality Director, Catalent Biologics and Tony Cundell Principal Consultant, Microbiological Consulting, LLC discuss some of the key microbiology and environmental monitoring challenges and trends in pharmaceutical manufacturing today.
Identification of environmental isolates is a regular requirement in pharmaceutical manufacturing, and strain differentiation can be valuable in a variety of circumstances. There have been huge advances in the technology available for sequencing bacterial genomes, which has fed through to the analyses that are available to pharmaceutical microbiologists. NCIMB’s Identification…
Discover how to improve your microbial identification process, reduce costs and protect your manufacturing process and brand reputation.
Tim Sandle explains how next-generation sequencing (NGS) could aid in the development of novel antimicrobials to overcome multi-drug resistance.
SGS's Center of Excellence for biosafety can help contribute to the fight against coronavirus.
Tecan’s range of advanced liquid handling solutions will soon be enhanced with the introduction of the new Fluent® Gx Automation Workstation*, designed specifically to meet the stringent needs of clinical and regulated laboratories...
7 November 2016 | By Jurgi Camblong, CEO and co-founder of Sophia Genetics
Sophia Genetics' CEO Jurgi Camblong says genomic data can now diagnose and tailor individual treatments but how do we democratise Data-Driven Medicine?
4 November 2015 | By New England BioLabs, Inc.
New Ultra II technology addresses lower input amounts and challenging sample types for Illumina® next generation sequencing systems...
In Issue #4 2015: NGS, Informatics, Spray Drying, Excipients, Rapid Methods, NIR, PAT, Regulatory Insight and much more...
3 September 2015 | By Joseph W. Wragg and Roy Bicknell, University of Birmingham
Over the past decade significant advances have been made in the fields of genomic and transcriptomic profiling, inspired by the advent of next-generation sequencing (NGS). Yet despite the considerable promise of these new technologies, uptake has been slow. The focus of this review is the use of next-generation transcriptomic analysis…
3 July 2014 | By René Dirks and Hendrik Marks, Department of Molecular Biology, Radboud Institute for Molecular Life Sciences (RIMLS)
Biomedical research often involves the use of cell lines that can be cultured in a laboratory. Individual cells within such cell lines often share a similar morphology. A remarkable exception are in vitro cultured mouse Embryonic Stem Cells (mESCs) – pluripotent cells derived from the blastocyst stage of the mouse…
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
Preclinical cancer models allow us to gain insight into therapeutic potential and mechanism of anti-cancer agents early in the drug discovery process. Whilst traditional array-based approaches have made a significant contribution to the characterisation of these models, the advent of next generation sequencing has revolutionised genomic research and is anticipated…
15 December 2013 | By Klarke M. Sample and Roy Bicknell, University of Birmingham
It is possible to attack the vasculature within solid tumours and achieve an anti-cancer effect. In the last decade, a number of studies have utilised cDNA libraries, SAGE analysis and microarrays to identify potential drug targets in the tumour endothelium. Modern sequencing technologies are likely to be a far more…
18 December 2012 | By Terry McCann, TJM Consultancy
The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion1. Herper1 observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of…
